US Ureteral Stents Market Size, Share, Trends and Forecasts 2031

Key Findings

• The US Ureteral Stents Market is expanding due to rising prevalence of urological disorders such as kidney stones, ureteral obstructions, and strictures.

• Increasing number of minimally invasive surgeries is boosting the demand for advanced stent designs in US.

• Growing geriatric population is driving higher adoption of ureteral stents for managing urinary complications.

• Rising cases of urolithiasis due to changing dietary habits and lifestyle factors are fueling market growth.

• Technological innovations such as biodegradable and drug-eluting stents are reshaping the competitive landscape.

• Healthcare infrastructure expansion and government support for urology treatments are accelerating adoption in US.

• Strategic collaborations between device manufacturers and hospitals are improving product accessibility.

• Stringent regulatory standards for stent safety and quality remain a challenge for new entrants.

US Ureteral Stents Market Size and Forecast

The US Ureteral Stents Market is projected to grow from USD 1.2 billion in 2025 to USD 2.1 billion by 2031, at a CAGR of 9.6% during the forecast period. Increasing incidence of kidney stones, tumors, and ureteral obstructions is driving demand for stent placements. Growing adoption of minimally invasive procedures, alongside rising hospital admissions for urinary complications, is boosting market penetration. Ongoing research in biodegradable and drug-eluting stents is expected to create future growth opportunities. Favorable reimbursement policies and the rising burden of lifestyle-related urological disorders in US are further accelerating market expansion.

Introduction

Ureteral stents are thin, flexible tubes inserted into the ureter to prevent or treat obstruction of urine flow from the kidney to the bladder. In US, they are widely used for conditions such as urolithiasis, postoperative management, and ureteral strictures. These stents are crucial for restoring urinary tract function, alleviating pain, and preventing complications such as hydronephrosis. Advancements in stent materials and coatings have significantly improved patient comfort and clinical outcomes. The growing demand for minimally invasive procedures, combined with rising urological disease prevalence, is propelling the use of ureteral stents across hospitals and specialty clinics in US.

Future Outlook

By 2031, the US Ureteral Stents Market will see strong growth driven by increasing awareness of early treatment for urological disorders and adoption of advanced stent technologies. Biodegradable stents will emerge as a game-changer, reducing the need for secondary removal procedures. Drug-eluting stents will further expand their role by preventing infections and minimizing encrustation risks. The geriatric population will remain a key contributor to demand, while emerging economies in US will benefit from improved healthcare infrastructure. Collaborations between medical device companies and healthcare providers will ensure wider accessibility, positioning US as a critical hub for urology-related device innovations.

US Ureteral Stents Market Trends

• Adoption of Minimally Invasive Urological Procedures
  The rising preference for minimally invasive surgeries in US is fueling demand for ureteral stents. Procedures such as ureteroscopy and percutaneous nephrolithotomy rely heavily on stent placement for postoperative management. Patients and healthcare providers are favoring minimally invasive solutions due to shorter recovery times, reduced complications, and lower hospital stays. With advancements in surgical techniques, stent placement is becoming safer and more effective. Hospitals are increasingly investing in specialized instruments and advanced stent systems. This trend is expected to strengthen with rising healthcare investments in US.

• Development of Biodegradable and Drug-Eluting Stents
  Technological advancements are driving the introduction of biodegradable and drug-eluting ureteral stents in US. These innovative stents minimize the need for secondary removal surgeries, improving patient compliance and outcomes. Drug-eluting variants reduce risks of infection and encrustation by releasing active agents over time. Medical device companies are investing heavily in R&D to optimize these next-generation stents. Clinical trials are showing promising results, accelerating regulatory approvals. This trend is reshaping competitive dynamics and positioning advanced stents as the future standard of care.

• Rising Burden of Kidney Stones and Urological Disorders
  The growing prevalence of kidney stones and related urinary tract disorders in US is significantly increasing demand for ureteral stents. Changing dietary habits, sedentary lifestyles, and dehydration are contributing to higher cases of urolithiasis. Hospitals are reporting a consistent rise in admissions for stone-related procedures. The high recurrence rates of kidney stones further amplify stent demand. As awareness of early diagnosis improves, more patients are opting for timely interventions. This trend will remain central to market expansion in the coming years.

• Focus on Patient Comfort and Stent Design Improvements
  Manufacturers in US are increasingly focusing on stent designs that enhance patient comfort and reduce complications. Innovations include stents with hydrophilic coatings, anti-reflux valves, and softer materials to minimize discomfort. Patient feedback is guiding product development, leading to designs that lower risks of migration and encrustation. Hospitals are adopting these advanced stents to improve patient satisfaction and treatment outcomes. The growing emphasis on quality of life post-procedure is driving continuous innovation. This trend will define the competitive landscape moving forward.

• Growing Collaborations Between Hospitals and Manufacturers
  Collaborations between hospitals, research institutions, and device manufacturers in US are accelerating the adoption of advanced ureteral stents. Joint ventures are enabling access to cutting-edge technologies and clinical expertise. These partnerships are also improving product availability in underserved regions. By integrating real-world feedback, companies are refining stent designs to better meet patient needs. Collaborative efforts are strengthening supply chains and reducing costs. This trend is expected to intensify as healthcare providers demand more specialized solutions.

Market Growth Drivers

• Increasing Prevalence of Urological Disorders
  The rising incidence of urolithiasis, strictures, and tumors in US is a major driver for the ureteral stents market. Changing lifestyles, poor hydration, and dietary habits are contributing to higher disease burden. Hospitals are reporting growing demand for stent placements as both temporary and long-term management solutions. The recurrence nature of kidney stones further strengthens the need for repeated stent use. This growing patient pool ensures sustained demand for stents across healthcare facilities. With increasing awareness and access to healthcare, adoption rates are expected to rise steadily.

• Technological Advancements in Stent Design
  Continuous innovations in stent materials, coatings, and designs are improving safety and efficacy in US. Advanced features such as biodegradable materials, drug-eluting coatings, and anti-migration designs are reducing patient complications. These innovations are making procedures more effective and improving recovery outcomes. Manufacturers are expanding their R&D investments to stay competitive. The adoption of such next-generation solutions is creating new growth opportunities. Technology-driven improvements will remain a long-term driver of market expansion.

• Rising Geriatric Population
  The aging population in US is increasingly prone to urological complications such as obstructions and kidney stones. Elderly patients often require frequent interventions, boosting demand for ureteral stents. Hospitals are witnessing higher admissions of elderly patients needing urinary support. Longer life expectancy and chronic disease prevalence are amplifying this trend. As the geriatric population continues to rise, it will remain a critical growth driver for the market. This demographic shift ensures consistent demand throughout the forecast period.

• Growing Preference for Minimally Invasive Surgeries
  Minimally invasive surgeries are becoming the preferred option for managing urological conditions in US. These procedures reduce hospital stays, improve patient comfort, and ensure faster recovery. Ureteral stents are essential in supporting these surgical interventions. Healthcare providers are increasingly adopting advanced stents to align with modern surgical practices. Rising training and awareness programs are further boosting adoption rates. The growing preference for minimally invasive procedures will sustain market momentum.

• Expansion of Healthcare Infrastructure
  Healthcare infrastructure improvements in US are expanding access to advanced urological treatments. Investments in hospitals, specialized urology centers, and medical devices are making stents more accessible. Governments and private players are focusing on reducing gaps in diagnosis and treatment. This expansion is particularly evident in emerging economies where demand for modern urology solutions is rising. Improved infrastructure is ensuring better availability of specialized products like ureteral stents. This driver will continue to support steady market growth.

Challenges in the Market

• Risk of Stent-Related Complications
  Ureteral stents are associated with complications such as infection, encrustation, migration, and patient discomfort in US. These risks often limit patient acceptance and increase the need for secondary interventions. Managing such complications adds to the overall treatment cost burden. Manufacturers are addressing these issues through innovations in coatings and designs. However, complications remain a significant restraint on adoption. Continuous improvements are necessary to overcome this challenge effectively.

• High Cost of Advanced Stents
  Next-generation stents such as drug-eluting and biodegradable variants are priced significantly higher in US. This makes them less accessible to patients in low- and middle-income regions. Limited reimbursement for advanced stents further discourages adoption. Cost constraints also restrict hospitals from widely stocking advanced products. Without broader affordability, market penetration remains uneven. Addressing pricing issues is essential to unlock full market potential.

• Stringent Regulatory Requirements
  Medical device regulations in US are becoming increasingly stringent, particularly for implantable devices like ureteral stents. Lengthy approval processes delay product launches. Smaller manufacturers face challenges in meeting compliance requirements due to limited resources. While regulations ensure patient safety, they add complexity and cost to product development. Delays in approvals can slow market expansion. Balancing innovation with regulatory compliance remains a challenge for the industry.

• Competition from Alternative Treatments
  Non-stent-based treatment methods such as laser lithotripsy or ureteroscopy without stenting are increasingly being adopted in US. In certain cases, these alternatives reduce the need for stents altogether. This trend limits overall demand growth in specific patient populations. Hospitals and physicians may choose these methods to reduce costs and complications. Manufacturers must focus on improving stent benefits to counter competition. The availability of alternatives remains a notable restraint in the market.

• Limited Awareness in Emerging Economies
  In some regions of US, limited patient and physician awareness restricts adoption of ureteral stents. Lack of specialized urology centers and trained professionals adds to the challenge. Patients often delay treatment due to low awareness of available interventions. Emerging economies face this challenge most prominently. Awareness campaigns and training programs are needed to overcome this restraint. Without these efforts, penetration rates may remain low in certain regions.

US Ureteral Stents Market Segmentation

By Product Type

• Double Pigtail Stents

• Metallic Stents

• Biodegradable Stents

• Drug-Eluting Stents

• Others

By Material

• Polyurethane

• Silicone

• Metallic Alloys

• Others

By Application

• Kidney Stones

• Ureteral Strictures

• Tumors

• Others

By End-User

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centers

• Others

Leading Key Players

• Boston Scientific Corporation

• Cook Medical

• Coloplast A/S

• B. Braun Melsungen AG

• Teleflex Incorporated

• Olympus Corporation

• Merit Medical Systems, Inc.

• C.R. Bard, Inc. (Becton, Dickinson and Company)

• Allium Medical Solutions Ltd.

• PNN Medical A/S

Recent Developments

• Boston Scientific Corporation launched a next-generation ureteral stent in US designed to reduce encrustation risks.

• Cook Medical expanded its portfolio in US with biodegradable stent offerings for improved patient outcomes.

• Coloplast A/S partnered with urology centers in US to enhance access to advanced stent solutions.

• B. Braun Melsungen AG invested in R&D facilities in US to develop drug-eluting ureteral stents.

• Teleflex Incorporated introduced patient-comfort-focused stents with hydrophilic coatings in US.

This Market Report Will Answer the Following Questions

1. What is the projected market size and growth rate of the US Ureteral Stents Market by 2031?

2. Which stent types and materials are most in demand in US?

3. How are technological advancements reshaping ureteral stent design and adoption?

4. What challenges such as costs and complications are restraining market growth?

5. Who are the leading players and innovators in the US Ureteral Stents Market?